NCT04001829 2026-04-21
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
Clinical Trials
72 trialsNCT05761171 2026-04-21
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
Phase 2 Active not recruiting
NCT02436707 2026-04-20
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04166565 2026-04-20
EMN19
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT00951535 2026-04-17
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT04195399 2026-04-15
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Children's Oncology Group
Phase 2 Active not recruiting
NCT01244789 2026-04-13
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Danish Gynecological Cancer Group
Phase 2 Active not recruiting
NCT03817398 2026-04-13
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
Children's Oncology Group
Phase 2 Active not recruiting
NCT02595424 2026-04-08
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03516279 2026-04-03
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05710328 2026-04-03
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01898494 2026-04-01
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01396408 2026-03-27
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04663997 2026-03-27
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03410615 2026-03-24
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04115631 2026-03-23
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04166318 2026-03-23
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04233866 2026-03-23
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04266249 2026-03-23
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04268550 2026-03-23
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT04316117 2026-03-23
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04597359 2026-03-23
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT02905318 2026-03-09
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04393285 2026-03-09
Abemaciclib and Letrozole to Treat Endometrial Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT03057106 2026-03-03
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT05154487 2026-03-03
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT01824875 2026-02-25
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT04176848 2026-02-18
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT02724579 2026-02-17
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT03822897 2026-02-17
EVADER
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT05714891 2026-02-12
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03965468 2026-02-09
CHESS
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT04743661 2026-02-05
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Pediatric Brain Tumor Consortium
Phase 2 Active not recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT03768570 2026-02-02
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03624543 2026-01-30
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT05601973 2026-01-21
AMAZE-lung
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT05673187 2026-01-21
ADEPPT
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT03480776 2026-01-14
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04203316 2026-01-09
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Children's Oncology Group
Phase 2 Active not recruiting
NCT03673124 2025-12-23
Ribociclib and Letrozole Treatment in Ovarian Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT04625647 2025-12-05
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT03834961 2025-12-02
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Children's Oncology Group
Phase 2 Active not recruiting
NCT04385277 2025-10-27
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 2 Active not recruiting
NCT02917720 2025-09-22
NAUT
European LeukemiaNet
Phase 2 Active not recruiting
NCT02972060 2025-09-19
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting